Deedwania P, Murphy SA, Scheen A, et al. - In the FOURIER randomized clinical trial, reduction in low-density lipoprotein cholesterol and cardiovascular events was achieved with providing the PCSK9 inhibitor evolocumab. Researchers here compared outcomes with evolocumab in patients with metabolic syndrome (MetS), who are at increased cardiovascular risk, vs those without MetS. In this prespecified analysis of the FOURIER randomized clinical trial of cases with atherosclerotic cardiovascular disease receiving statin, they assessed 16,361 individuals with metabolic syndrome and 10,981 patients without metabolic syndrome. Individuals with metabolic syndrome were noted to be at higher risk for cardiovascular events relative to those without. In these high-risk patients, evolocumab, vs placebo, led to significant decrease in low-density lipoprotein cholesterol and the risk of cardiovascular events without enhancing the risk of safety events, new-onset diabetes, or worsening glycemic control. .